149 results on '"Lucas, Jose J."'
Search Results
2. Pathogenic Mis-splicing of CPEB4 in Schizophrenia
3. Correction to: CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington’s disease
4. CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in huntington’s disease
5. Huntingtin-mediated axonal transport requires arginine methylation by PRMT6
6. Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome
7. Regulation of proteasome activity by P2Y2 receptor underlies the neuroprotective effects of extracellular nucleotides
8. The anti-leprosy drug clofazimine reduces polyQ toxicity through activation of PPARγ
9. Reduced striatal dopamine DA D2 receptor function in dominant-negative GSK-3 transgenic mice
10. Co-expression of FTDP-17 Human Tau and GSK-3ß (or APPSW) in Transgenic Mice: Induction of Tau Polymerization and Neurodegeneration
11. Mutant huntingtin affects endocytosis in striatal cells by altering the binding of AP-2 to membranes
12. Age-dependent decline of motor neocortex but not hippocampal performance in heterozygous BDNF mice correlates with a decrease of cortical PSD-95 but an increase of hippocampal TrkB levels
13. Pharmacokinetic behavior of marbofloxacin after intravenous, subcutaneous and intramuscular administrations in llamas (Lama glama)
14. Additional file 3 of CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington’s disease
15. Additional file 6 of CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in huntington’s disease
16. Additional file 15 of CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington’s disease
17. Additional file 5 of CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington’s disease
18. Additional file 2 of CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington’s disease
19. Additional file 7 of CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington’s disease
20. Additional file 4 of CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in huntington’s disease
21. Additional file 8 of CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington’s disease
22. Accumulation of Ubiquitin Conjugates in a Polyglutamine Disease Model Occurs without Global Ubiquitin/Proteasome System Impairment
23. Impaired ATF6α processing, decreased Rheb and neuronal cell cycle re-entry in Huntington's disease
24. Huntington's disease is a four-repeat tauopathy with tau nuclear rods
25. Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits
26. Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism
27. GSK3: A possible link between beta amyloid peptide and tau protein
28. Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: Role in excitotoxicity
29. Effects of partial suppression of parkin on huntingtin mutant R6/1 mice
30. F16. THE PURINE METABOLISM IN MENTAL ILLNESSES: THE ROLE OF THE CANCER GENE FHIT ACROSS PSYCHIATRIC DISEASES
31. NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy
32. Choosing the Equation for Estimated Gestational Age With Crown-Rump Length
33. N-terminal Cleavage of GSK-3 by Calpain: A NEW FORM OF GSK-3 REGULATION
34. A mouse model to study tau pathology related with tau phosphorylation and assembly
35. Role of tau protein in both physiological and pathological conditions
36. Testing the ubiquitin--proteasome hypothesis of neurodegeneration in vivo
37. CHOP regulates the p53–MDM2 axis and is required for neuronal survival after seizures
38. Cooexpression of FTDP-17 tau and GSK-3β in transgenic mice induce tau polymerization and neurodegeneration
39. CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington’s disease
40. Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease
41. Glycogen Synthase Kinase-3 Plays a Crucial Role in Tau Exon 10 Splicing and Intranuclear Distribution of SC35: IMPLICATIONS FOR ALZHEIMER'S DISEASE
42. New players in the 5-HT receptor field: genes and knockouts
43. Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418
44. GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms
45. Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor
46. Sulfo-glycosaminoglycan content affects PHF-tau solubility and allows the identification of different types of PHFs
47. Modulation of the effects of cocaine by 5-HT1B receptors: a comparison of knockouts and antagonists
48. Targeting the proteasome in epilepsy
49. Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury
50. Overexpression of synphilin-1 promotes clearance of soluble and misfolded alpha-synuclein without restoring the motor phenotype in aged A30P transgenic mice.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.